23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › AngioDynamics, Inc. › 2025-2026

AngioDynamics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and AngioDynamics, Inc.’s Form 8-K, filed November 12, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 190Asset managers, any item
  • 801Fund votes
  • November 10, 2025Meeting date

Results at a glance

Meeting of November 10, 2025: 4 items on AngioDynamics, Inc.’s Form 8-K, filed November 12, 2025: 2 elected · 2 approved.

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AngioDynamics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by AngioDynamics, Inc.

These tallies are AngioDynamics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed November 12, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AngioDynamics, Inc. — official shareholder meeting results, meeting held November 10, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: James C. Clemmer 29,634,152---- 800,4545,462,943 97%Elected—
Elect Director: Michael E. Tarnoff, MD 29,245,896---- 1,188,7105,462,943 96%Elected—
2. Proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public accounting firm for the fiscal year ending May 31, 2026 35,727,186156,89913,464 ---- 99.6%Approved—
3. Proposal to approve, on an advisory basis, AngioDynamics' executive compensation of its named executive officers 28,357,7822,057,98218,842 --5,462,943 93%Approved—

Source: AngioDynamics, Inc., Form 8-K, filed with the SEC on November 12, 2025 — read the filing on EDGAR.

How asset managers voted at the AngioDynamics, Inc. 2025-2026 meeting

190 asset managers disclosed a vote on at least one AngioDynamics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: James C. Clemmer

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 29,634,152WITHHELD: 800,454
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Proposal to elect two Class I directors, for a term of three years: James C. Clemmer

AngioDynamics, Inc.’s own tally for this item (“Elect Director: James C. Clemmer”): 29,634,152 for, 800,454 withheld, per its Form 8-K filed November 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The nominees for election to the Board of Directors were elected, each as a Class I director to serve until the 2028 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 9,331,457 for, 299 withheld, 1,135 abstained.

FOR
FOR: 9,331,457ABSTAIN: 1,135WITHHOLD: 299
Largest asset managers voting on “Proposal to elect two Class I directors, for a term of three years: James C. Clemmer” at AngioDynamics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,076,8820 00For
BlackRock1,612,5220 00For
TIAA1,012,6270 00For
Fidelity991,0960 00For
Royce553,4610 00For
Dimensional499,0170 00For
Charles Schwab330,9880 00For
Segall Bryant & Hamill Trust322,7470 00For
Transamerica304,0000 00For
FIRST EAGLE FUNDS243,2210 00For
PARADIGM FUNDS200,0000 00For
Columbia Threadneedle126,9020 00For
RBB FUND, INC.119,7240 00For
Equitable104,7440 00For
American Century96,9050 00For
State Street92,0510 0124For
Dunham Funds80,8070 00For
1290 Funds72,4650 00For
QUANTITATIVE MASTER SERIES LLC69,0580 00For
Lincoln Financial62,9950 00For
Goldman Sachs54,2640 00For
SEI51,7770 00For
MASTER INVESTMENT PORTFOLIO31,1090 00For
Northern Trust25,3760 00For
AIG/SunAmerica20,0540 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: Michael E. Tarnoff, MD

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 29,245,896WITHHELD: 1,188,710
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Proposal to elect two Class I directors, for a term of three years: Michael E. Tarnoff, MD

AngioDynamics, Inc.’s own tally for this item (“Elect Director: Michael E. Tarnoff, MD”): 29,245,896 for, 1,188,710 withheld, per its Form 8-K filed November 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The nominees for election to the Board of Directors were elected, each as a Class I director to serve until the 2028 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 9,319,940 for, 11,816 withheld, 1,135 abstained.

FOR
FOR: 9,319,940ABSTAIN: 1,135WITHHOLD: 11,816
Largest asset managers voting on “Proposal to elect two Class I directors, for a term of three years: Michael E. Tarnoff, MD” at AngioDynamics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,076,8820 00For
BlackRock1,612,5220 00For
TIAA1,012,6270 00For
Fidelity991,0960 00For
Royce553,4610 00For
Dimensional499,0170 00For
Charles Schwab330,9880 00For
Segall Bryant & Hamill Trust322,7470 00For
Transamerica304,0000 00For
FIRST EAGLE FUNDS243,2210 00For
PARADIGM FUNDS200,0000 00For
Columbia Threadneedle126,9020 00For
RBB FUND, INC.119,7240 00For
Equitable104,7440 00For
American Century96,9050 00For
State Street92,0510 0124For
Dunham Funds80,8070 00For
1290 Funds72,4650 00For
QUANTITATIVE MASTER SERIES LLC69,0580 00For
Lincoln Financial62,9950 00For
Goldman Sachs54,2640 00For
SEI51,7770 00For
MASTER INVESTMENT PORTFOLIO31,1090 00For
Northern Trust25,3760 00For
AIG/SunAmerica20,0540 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Proposal to approve, on an advisory basis, AngioDynamics' executive compensation of its named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%
FOR: 28,357,782AGAINST: 2,057,982

Prior year: 95.4% for (November 12, 2024 meeting) ▼ 2.2 pts

Details: description as filed, official tally, votes by 187 asset managers

Description as filed by funds: Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers.

AngioDynamics, Inc.’s own tally for this item (“3. The proposal to approve, on an advisory basis, AngioDynamics' executive compensation of its named executive officers”): 28,357,782 for, 2,057,982 against — passed, per its Form 8-K filed November 12, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal to approve, on an advisory basis, AngioDynamics' executive compensation of its named executive officers was approved based upon the following votes:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 53 asset managers voting on “Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers.” at AngioDynamics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,076,8820 00For
BlackRock1,612,5220 00For
TIAA1,012,6270 00For
Fidelity991,0960 00For
Royce553,4610 00For
Dimensional499,0170 00For
Charles Schwab330,9880 00For
Segall Bryant & Hamill Trust322,7470 00For
Transamerica304,0000 00For
FIRST EAGLE FUNDS243,2210 00For
PARADIGM FUNDS200,0000 00For
Columbia Threadneedle126,9020 00For
RBB FUND, INC.119,7240 00For
Equitable104,7440 00For
American Century096,905 00Against
State Street92,1750 00For
Dunham Funds80,8070 00For
1290 Funds72,4650 00For
QUANTITATIVE MASTER SERIES LLC69,0580 00For
Lincoln Financial62,9950 00For
Goldman Sachs54,2640 00For
SEI51,7770 00For
MASTER INVESTMENT PORTFOLIO31,1090 00For
Northern Trust25,3760 00For
AIG/SunAmerica20,0540 00For

Fund voting reports, all 53 managers: 9,228,306 for, 104,585 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 148 asset managers voting on “Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers.” at AngioDynamics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Point722,090,3460 00For
BlackRock1,548,490400 00For
ARMISTICE CAPITAL, LLC1,432,1000 00For
SYSTEMATIC FINANCIAL MANAGEMENT LP1,383,06012,605 00For
Divisadero Street Capital Management, LP1,387,4700 00For
Nuveen1,015,1470 00For
GEODE CAPITAL MANAGEMENT, LLC987,4730 00For
SEGALL BRYANT & HAMILL, LLC939,5250 00For
State Street841,3490 00For
Renaissance666,0250 00For
PARADIGM CAPITAL MANAGEMENT INC/NY518,2000 00For
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM0517,284 00Against
Pier Capital, LLC453,9530 00For
Royce438,8990 00For
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP408,0610 00For
Manatuck Hill Partners, LLC333,0580 00For
Charles Schwab331,0380 00For
Invesco0314,742 00Against
Orion Porfolio Solutions, LLC289,3900 00For
First Eagle Investment Management, LLC277,3350 00For
Northern Trust269,5800 00For
Two Sigma199,7070 00For
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM196,1580 00For
KENNEDY CAPITAL MANAGEMENT LLC194,7130 00For
MOORE CAPITAL MANAGEMENT, LP190,6750 00For

Institutional-manager reports, all 148 managers: 18,787,519 for, 952,489 against, 1,594 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public accounting…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.6% Approved · of votes cast

FOR 99.6%
FOR: 35,727,186AGAINST: 156,899

Prior year: 99.5% for (November 12, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as AngioDynamics, Inc. independent registered public accounting firm for the fiscal year ending May 31, 2026.

AngioDynamics, Inc.’s own tally for this item (“2. The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public accounting firm for the fiscal year ending May 31, 2026”): 35,727,186 for, 156,899 against — passed, per its Form 8-K filed November 12, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public accounting firm for the fiscal year ending May 31, 2026 was approved based upon the following votes:”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 9,329,848 for, 3,043 against.

FOR
FOR: 9,329,848AGAINST: 3,043
Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as AngioDynamics, Inc. independent registered public accoun” at AngioDynamics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,076,8820 00For
BlackRock1,612,5220 00For
TIAA1,012,6270 00For
Fidelity991,0960 00For
Royce553,4610 00For
Dimensional499,0170 00For
Charles Schwab330,9880 00For
Segall Bryant & Hamill Trust322,7470 00For
Transamerica304,0000 00For
FIRST EAGLE FUNDS243,2210 00For
PARADIGM FUNDS200,0000 00For
Columbia Threadneedle126,9020 00For
RBB FUND, INC.119,7240 00For
Equitable104,7440 00For
American Century96,9050 00For
State Street92,1750 00For
Dunham Funds80,8070 00For
1290 Funds72,4650 00For
QUANTITATIVE MASTER SERIES LLC69,0580 00For
Lincoln Financial62,9950 00For
Goldman Sachs54,2640 00For
SEI50,0441,733 00For
MASTER INVESTMENT PORTFOLIO31,1090 00For
Northern Trust25,3760 00For
AIG/SunAmerica20,0540 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Largest AngioDynamics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 41,004,249 shares outstanding at the time of that meeting.

Fund voting reports: top AngioDynamics, Inc. shareholders by shares voted on “Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 5.07%
2BlackRock 3.93%
3TIAA 2.47%
4Fidelity 2.42%
5Royce 1.35%
6Dimensional 1.22%
7Charles Schwab 0.81%
8Segall Bryant & Hamill Trust 0.79%
9Transamerica 0.74%
10FIRST EAGLE FUNDS 0.59%
Institutional-manager reports: top AngioDynamics, Inc. shareholders by shares voted on “Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Point72 5.10%
2BlackRock 3.78%
3ARMISTICE CAPITAL, LLC 3.49%
4SYSTEMATIC FINANCIAL MANAGEMENT LP 3.40%
5Divisadero Street Capital Management, LP 3.38%
6Nuveen 2.48%
7GEODE CAPITAL MANAGEMENT, LLC 2.41%
8SEGALL BRYANT & HAMILL, LLC 2.29%
9State Street 2.05%
10Renaissance 1.62%

Reported AngioDynamics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

AngioDynamics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock3,685,904 8.99%Form 13F, quarter ended March 31, 2026
Point723,181,829 7.76%Form 13F, quarter ended March 31, 2026
SYSTEMATIC FINANCIAL MANAGEMENT LP2,508,295 6.12%Schedule 13G, filed February 10, 2026
Vanguard Group2,436,833 5.94%Form 13F, quarter ended March 31, 2026
KEVIN KOTLER2,421,526 5.91%Schedule 13G, filed February 9, 2026
State Street1,333,858 3.25%Form 13F, quarter ended March 31, 2026
James C. Clemmer1,117,665 2.73%Proxy statement (DEF 14A), proxy filed September 25, 2025
Dimensional Fund Advisors948,815 2.31%Form 13F, quarter ended March 31, 2026
Renaissance Technologies803,283 1.96%Form 13F, quarter ended March 31, 2026
Millennium Management644,677 1.57%Form 13F, quarter ended March 31, 2026

Percentages above are of 41,004,249 shares outstanding, as reported by AngioDynamics, Inc. on its Form 10-Q dated August 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At AngioDynamics, Inc.'s shareholder meeting held November 10, 2025, in the 2025-2026 proxy season, 190 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 801 separate fund positions. On the most widely held item on that ballot — Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers. — AngioDynamics, Inc.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AngioDynamics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on November 12, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AngioDynamics, Inc.’s 10-Q dated August 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

AngioDynamics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “AngioDynamics (ANGO) 2025 Annual Meeting (2025-2026 season)”, https://proxyvotesnow.com/company/angiodynamics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.